INTRODUCTION
It is well established that there is a high incidence of primary hyperparathyroidism in patients with medullary thyroid carcinoma (1) (2) (3) . The cause for this association is not well established, but it may have either a genetic or functional basis (3) (4) (5) . To patients with medullary thyroid carcinoma. Hormone measurements were made in the basal state and during tests of hormone secretion. Our results suggest that there may be a functional relationship between the secretion of PTH and CT in patients with medullary thyroid carcinoma.
METHODS
30 patients with histologically proven medullary thyroid carcinoma were studied; most patients had a family history of this tumor. Basal measurements of PTH, CT, and calcium were made in each patient. All studies were performed before any neck surgery. 18 calcium infusions were performed in 10 patients. For 13 of the infusion studies, calcium as the chloride salt was infused at a rate of 5 mg/ kg/h for 3-4 h. In one infusion (Table I, no. 3), calcium was given at a rate of 0.5 mg/kg/h for 3 h. In five infusions (Table I , nos. 6, 7, 15, 16, 18) , 150 mg of calcium was given in 50 ml of normal saline over 5-10 min.
Blood samples were collected for calcium and hormone measurements at hourly intervals during the 3-4 h infusions and at 10-15-min intervals for up to 3 h after the short calcium infusions. CT and PTH were measured by previously described radioimmunoassays (7) (8) (9) (10) . The antiserum used for PTH measurement reacts with both the amino terminus and carboxy terminus of the PTH molecule (9, 10) . All samples were measured in replicate assays at multiple dilutions. Phase separation was accomplished by charcoal-coated dextran (10) . Intra-and interassay variation were 10 and 20%, respectively. The normal range for PTH in this assay system is 200-800 pg/ml of human PTH; however, there is some overlap among subjects with normal and abnormal parathyroid function (9, 11) . In our CT assay, most normal subjects have hormone concentrations of less than 100 pg/ml (12) . Calcium was measured by atomic absorption spectrophotometry. RESULTS Fig. 1 (10.8-14 .0 mg/100 ml), five had elevated basal levels of PTH, and one had a concentration of 630 pg/ml, which was inappropriately high for the calcium of 11.6 mg/100 ml. The remaining calcium abnormality, found in one patient (not infused), was hypocalcemia (7.9 mg/100 ml), presumably on the basis of diarrhea and malabsorption. Table I summarizes all of the data in the 18 calcium infusions. Fig. 2 shows the changes in PTH that occurred during the infusions. In 12 of the studies, there was an unanticipated increase in PTH after the infusion of calcium. In these 12 subjects, calcium infusion led to a mean increase in PTH of 485%. Although PTH was suppressed in 6 calcium infusions, for all 18 of the calcium infusions, there was still a mean increase in PTH of 308%. When the increases in PTH during the calcium infusions were rank ordered, they correlated directly with the increases in CT during the infusion (r = 0.76, P < 0.001) and correlated inversely with the increase in calcium during the infusion (r = -0.62, P < 0.01) (13) . In five normal subjects, the short (150 mg) calcium infusion either suppressed or had no effect on plasma PTH. In three patients, it was possible to compare the effects of two types of calcium infusion on PTH (Figs. 3 and 4). In one of these patients (Fig. 3) (Fig. 4) , two standard (15 mg/kg/3 h) calcium infusions (Fig. 4, right) (Fig. 4 left) Calcium infusion did result in the expected increase in CT concentration in these patients (Table I) . However, two-thirds of the calcium infusions led to an unexpected increase in PTH (Fig. 2) crease in PTH during calcium infusion is that the abnormal increase in CT that occurs in these patients during the infusion is a stimulus to PTH secretion: in those infusions in which there is also a marked increase in calcium, the rise in calcium may counteract this proposed stimulatory effect of CT on PTH; in those infusions in which there is only a small increase in calcium, the stimulatory effect of CT on PTH becomes manifest.
We were able to test this hypothesis directly in three of our patients with medullary thyroid carcinoma. In one (Fig. 3) , a low dose calcium infusion (Table I,  no. 3), which produced a 63% increase in CT but only an 0.4-mg increase in calcium, resulted in almost a doubling of PTH; in the same patient, a standard dose calcium infusion (Table I , no. 4), which increased calcium by 4.3 mg but only increased CT by 17%, resulted in a suppression of PTH secretion. In another patient, two standard dose (Table I , nos. 13 and 14) and two low dose (Table I , nos. 15 and 16) calcium infusions were performed (Fig. 4) (2, 12, 14) , and studies of their effects are in progress. However, the variable effect of both glucagon and gastrin on CT secretion may make such studies difficult to interpret (15) (16) (17) (18) .
Parathyroid Hormone in Medullary Thyroid Carcinoma
Although our results do suggest a functional relationship between hyperparathyroidism and medullary thyroid carcinoma, these observations cannot be interpreted to indicate that CT has a direct effect on PTH secretion in normal subjects. The peripheral concentration of CT in our patients is much higher than ever seen in normal subjects, and the concentration in the vicinity of the parathyroid glands may be even much higher. Therefore, this apparent direct stimulation of PTH by CT should be considered a pharmacological effect at this time.
However, our observations do suggest that, under certain circumstances, CT may stimulate the secretion of PTH; this effect may play some role in the high incidence of hyperparathyroidism in patients with medullary thyroid carcinoma. This view is supported by in vitro studies which demonstrate that large doses of CT increase the secertion of PTH by porcine parathyroid gland slices (19) . Although Melvin Tashjian, and Miller (3) did not observe any increase in PTH during calcium infusion in six patients with medullary thyroid carcinoma, a standard calcium infusion was used that increased plasma calcium up to 13-14 mg/ 100 ml; this marked increase in calcium may have countered any stimulatory effect of CT on PTH. In addition, one of their patients did' not exhibit the expected decrease in PTH during the calcium infusion. A difference in specificity of the immunoassay procedures for PTH used in our study and in the study of Melvin et al. may also explain some of the discrepancies. The PTH antisera used in this study has reactivity that spans the linear sequence of the molecule (9-11). Melvin et al. do not give any data regarding the specificity of their PTH antisera. In any case, additional studies should be designed to investigate further the relationship between CT and PTH in patients with medullary thyroid carcinoma.
